Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B - Marcellin, Patrick; Ahn, Sang Hoon; Ma, Xiaoli; Caruntu, Florin A.; Tak, Won Young; Elkashab, Magdy; Chuang, Wan-Long; Lim, Seng-Gee; Tabak, Fehmi; Mehta, Rajiv; Petersen, Joerg; Foster, Graham R.; et al. (Gastroenterology (New York, N.Y. 1943), 2016)
Keywords: Administration, Oral; Adolescent; Adult; Aged; Clinical Trial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastroenterology and Hepatology; HBeAg Seroconversion; HBV; Hepatitis B Surface Antigens - blood; Hepatitis B Surface Antigens - drug effects; Hepatitis B, Chronic - blood; Hepatitis B, Chronic - diagnosis; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - mortality; Humans; Injections, Subcutaneous; Interferon-alpha - therapeutic use; Internationality; Kaplan-Meier Estimate; Male; Markov Chains; Middle Aged; Polyethylene Glycols - therapeutic use; Prognosis; Recombinant Proteins - therapeutic use; Risk Assessment; Severity of Illness Index; Survival Rate; Tenofovir - therapeutic use; Treatment Outcome; Viral Load - drug effects; Virologic Response; Young Adult; Virologic Response; HBeAg Seroconversion; Clinical Trial; HBeAg; TDF; ALT; HBsAg; CHB; HBV; S/CO; peginterferon; chronic hepatitis B; sample/cutoff relative light units of quantitative HBsAg; hepatitis B surface antigen; hepatitis B virus; alanine aminotransferase; tenofovir disoproxil fumarate; hepatitis B e antigen; pegylated interferon-α